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Abstract 25 
On-demand relief of local pain would allow patients to control the timing, intensity and duration 26 
of nerve block in a safe and non-invasive manner. Ultrasound would be a suitable trigger for 27 
such a system, as it is in common clinical use and can penetrate deeply into the body. Here, we 28 
demonstrate that ultrasound-triggered delivery of an anaesthetic from liposomes allows the 29 
timing, intensity and duration of nerve block to be controlled by ultrasound parameters. On 30 
insonation, the encapsulated sonosensitizer protoporphyrin IX produces reactive oxygen species 31 
that react with the liposomal membrane, leading to the release of the potent local anaesthetic 32 
tetrodotoxin. We also show repeatable ultrasound-triggered nerve blocks in vivo, with nerve-33 
block duration depending on the extent and intensity of insonation. We did not detect any 34 
systemic toxicity, and tissue reaction was benign in all groups. On-demand, personalized local 35 
anaesthesia could be beneficial for the managing of relatively localized pain states, and 36 
potentially minimize opioid use.  37 
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Introduction 38 
Current treatments of perioperative and other forms of relative acute pain are limited, relying 39 
heavily on opioids and local anesthetics. Opioids are a mainstay of pain treatments, but are 40 
systemic therapies associated with clouding of the sensorium and the potential for tolerance, 41 
addiction, diversion, and overdose. Local anesthetics are effective in perioperative and other 42 
forms of acute pain, and can be applied throughout a tissue (infiltration local anesthesia), or 43 
around a specific nerve or group of nerves (regional anesthesia); in the latter case, they can be 44 
effective even when applied at a distance from the injured area or surgical site. However, free 45 
local anesthetic solutions tend to be relatively brief in duration. Formulations have been 46 
developed that provide approximately one week of nerve block following a single 47 
administration1, 2. However, drug release from such systems cannot be adjusted in response to 48 
changes in the patient’s needs. Safe and on-demand local pain relief that allows patients to 49 
control the timing, intensity and duration of analgesia according to their changing needs and 50 
conditions would have a marked impact on the management of acute pain, and could reduce or 51 
obviate the use of opioids. 52 
Remotely-triggered drug delivery systems have been developed that can address the need to 53 
modulate pharmacological effects in real time. We have developed injectable on-demand local 54 
anesthetic systems 3, 4 that can be triggered by near-infrared light. The difficulty with light as a 55 
trigger is that its penetration of tissue may be limited 5; that limitation may be overcome by 56 
increasing the irradiance, but at the risk of causing burns 6, 7.  57 
Ultrasound is non-invasive, can penetrate deep into tissues and it can be applied in a focused 58 
manner such that the energy applied in surrounding, non-targeted tissues can be minimized 8, 9. 59 
Ultrasound is already common in clinical practice, for both diagnostic and therapeutic purposes. 60 
Nerve block injections are widely guided by ultrasound in the clinic, with an associated 61 
reduction in injection-related complications10 and an increase in success rate11. An on-demand 62 
nerve block system that could use readily available ultrasound clinical devices might ease 63 
clinical translation of on-demand drug delivery systems in pain management.  64 
Many of the current ultrasound-triggerable drug delivery systems, such as micelles12, 65 
liposomes13, composites14 and hybrid15 materials, are responsive to the thermal and mechanical 66 
effects of ultrasound waves. Ultrasound can also induce sonochemistry, the use of ultrasound to 67 
carry out chemical reactions16. Sonodynamic therapy (SDT) has been proposed as an analogous 68 
strategy to photodynamic therapy (PDT), in which a sonosensitizer is activated by acoustic 69 
energy to generate reactive oxygen species (ROS)8. However, the generation of ROS by this 70 
effect remains largely unexplored for triggering the release of drugs17.   71 
Here we developed a liposome-based system to provide ultrasound-triggered repeatable on-72 
demand local anesthesia (Scheme S1). Ultrasound energy encountering the liposomes will cause 73 
a sonosensitizer to release ROS, peroxidating unsaturated lipids in the bilayers, leading to release 74 
of local anesthetics which would induce nerve block. As the sonosensitizer18, we selected 75 
protoporphyrin IX (PPIX), a naturally- occurring intermediate of heme biosynthesis19 and the 76 
active component of the FDA-approved pro-drug 5-aminolevulinic acid (ALA)20. The 77 
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hydrophilic site 1 sodium channel blocker, tetrodotoxin (TTX), was chosen as the encapsulated 78 
local anesthetic due to its ultra-high potency and minimal myo-21 and neuro22-toxicity. Clinical 79 
trials of systemic TTX for cancer pain demonstrated the potential safety of this drug 23, 24. 80 
Results  81 
Liposome preparation and in vitro evaluation 82 
PPIX was encapsulated in liposomes consisting of unsaturated lipid (1,2-dilinoleoyl-sn-glycero-83 
3-phosphocholine; DLPC), saturated lipid (1,2- distearoyl-sn-glycero-3-phosphocholine; DSPC), 84 
1,2-distearoyl-sn-glycero-3-phosphatidylglycerol (DSPG), and cholesterol. The mean size was 85 
3.1 ± 0.9 µm (Figure S1). Ultrasound application did not induce statistically significant changes 86 
in liposome size (p=0.95, N=4), (Figure S1).  87 
ROS production under insonation was measured by a fluorescent indicator, Carboxy-88 
H2DCFDA. Carboxy-H2DCFDA was added in the liposome solution and the production of ROS 89 
upon insonation was measured (Figure 1a); maximal ROS production occurred at a PPIX loading 90 
of 0.3% [mg PPIX/mg (PPIX+lipid) X 100 %]. This ROS production was associated with lipid 91 
peroxidation; the extent of peroxidation (see Methods) increased with increasing duration of 92 
insonation (Figure 1b). The effect of PPIX loading on ultrasound triggerability of drug release 93 
was evaluated in liposomes encapsulating the fluorescent dye sulforhodamine B (Lipo-PPIX-94 
SRho; Figure 1) as reported 4, 25. Sulforhodamine B (SRho) was loaded into liposomes by 95 
hydrating the liposomal lipid cake with a highly concentrated SRho aqueous solution, due to the 96 
hydrophilicity of SRho. The dye was encapsulated at a concentration where self-quenching 97 
resulted in low fluorescence; once SRho was released, its fluorescence increased, which was 98 
measured to determine SRho release. The greatest dye release under ultrasound application 99 
(3W/cm2, continuous application, 1 MHz, 10 min) occurred at 0.3 % loading (Figure 1c). In 100 
liposomes made with DSPC which is a saturated lipid, instead of the unsaturated and 101 
peroxidizable DLPC, dye release from insonation was greatly reduced (Figure 1c, DPLC 102 
negative group). Consequently, 0.3 % PPIX was used in all subsequent experiments. 103 
The release of dye from Lipo-PPIX-SRho was dependent on the frequency, duration, 104 
intensity and duty cycle of insonation (Figure 1d-f). Based on these results, an ultrasound 105 
frequency of 1 MHz, intensity of 3 W/cm2, and 100% duty cycle were used for subsequent 106 
experiments in this study unless otherwise stated. Two durations of insonation were used: 10 min 107 
to examine the effect of a single pulse on cargo release, and 5 min when assessing the effects of 108 
repeated pulses. (The shorter duration resulted in less release and therefore allowed more 109 
triggered events.) Dye release could be repeatedly triggered from liposomes by repeated 110 
insonation (3W/cm2, 1 MHz, 5 min; Figure 2a), with up to 4 triggerable events releasing 4.3 ± 111 
0.8%, 4.5 ± 0.9%, 8.2 ± 2%, and 6.0 ± 0.9% respectively.  112 
To demonstrate that generation of ROS was the likely mechanism of triggered release, we 113 
irradiated Lipo-PPIX-SRho (PPIX 0.9 µg/mL, see Methods for details) with 400 nm light, which 114 
can cause PPIX to generate reactive oxygen species 26. Lipo-PPIX-SRho irradiated at 5 mW/cm2 115 
for 10 min released 9.3% ± 1.8% of their dye payload (Figure S2). Lipo-SRho irradiated under 116 
the same conditions released very little dye (Figure S2). 117 
The mechanical properties of blank liposomes (Lipo) and liposomes loaded with PPIX (Lipo-118 
PPIX) were measured using atomic force microscopy (AFM). Liposomes were immobilized on a 119 
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3-triethoxysilylpropylamine-functionalized Si wafer and their elastic moduli were measured (see 120 
Methods for details). The mean elastic modulus of Lipo was 20.3 ± 6.2 kPa, and that of Lipo-121 
PPIX was 217.3 ± 71.1 kPa (P value comparing the two = 0.00079). These results demonstrate 122 
that the addition of PPIX to the liposomal formulation increased the elastic modulus of the 123 
liposomal bilayers, i.e. made them less susceptible to mechanical effects of insonation. These 124 
results suggest that the release of TTX from Lipo-PPIX is more likely to have been attributable 125 
to ultrasound-induced sonochemistry than to the mechanical effects of ultrasound. 126 
The dye-filled liposomes were injected subcutaneously to screen whether the ultrasound-127 
triggered response would function in vivo. Subcutaneous application (e.g. for infiltration 128 
anesthesia) is only one of many sites at which this system could be used to provide local 129 
anesthesia. Ultrasound-triggered release of dye from subcutaneously injected Lipo-PPIX-SRho 130 
was demonstrated in vivo with an animal fluorescence imaging system (Figure 2b). Upon 131 
insonation (3W/cm2, 1 MHz, 10 min), the fluorescence in the injection area increased by 56 ± 132 
9% (N=4; P < 0.001).  133 
Ultrasound-triggered TTX release in vitro 134 
TTX was encapsulated in PPIX-loaded liposomes (Lipo-PPIX-TTX; Figure 3a) with a mean size 135 
of 2.8 ± 0.5 µm. The loading efficiencies of TTX and PPIX were 22.2 ±0.2 % and 79.1 ±8.5 % 136 
respectively (Table S1), comparable to results from previous studies of TTX loaded liposomes3.  137 
To confirm that TTX release was also triggerable from PPIX-loaded liposomes, in vitro TTX 138 
release was assessed by dialyzing 150 µL of Lipo-PPIX-TTX against 14 mL of PBS (Figure 3b-139 
c). 7.1 ±1.0 % of TTX was released within the first 4 h, followed by a slower release of 140 
approximately 0.4 % / h (Figure 3b). Ultrasound (3W/cm2, 1 MHz, 10 min) applied at the 5 h 141 
time point induced a release of 5.4 ± 2.6 % of TTX over the next 4 h (Figure 3b). Without 142 
ultrasound 1.4 ± 1.0 % was released over the same period. Liposomes loaded with TTX but 143 
without PPIX (Lipo-TTX) showed comparable TTX loading to Lipo-PPIX-TTX (Table S1), but 144 
TTX release was faster in the absence of PPIX: initial release was 19.6 ± 5.7 % in the first 4 h, 145 
after which release leveled off (Figure 3c). Ultrasound applied to Lipo-TTX at the 5 h time point 146 
did not trigger TTX release. Comparing the release profile of Lipo-PPIX-TTX and Lipo-TTX, 147 
we find that in the first hour, release from Lipo-TTX (Figure 3c) was more than twice that from 148 
Lipo-PPIX-TTX (p = 0.02; Figure 3b); by 2 h the difference was almost three-fold (p< 0.01). 149 
These results show that PPIX was necessary for ultrasound-triggered TTX release. 150 
Lipo-PPIX-TTX and Lipo-TTX (TTX liposomes without PPIX) were insonated, and TTX 151 
was extracted as described 42 and quantified by ELISA. Insonation, and the resulting production 152 
of ROS, did not affect the concentration of TTX in Lipo-PPIX-TTX (Figure S3). 153 
 154 
Ultrasound-triggered sciatic nerve blockade in vivo 155 
Liposomes were injected at the rat sciatic nerve, and nerve blockade was assessed by 156 
neurobehavioral testing with a modified hot-plate test (see Methods section). In these 157 
experiments, the principal metric of nerve block was the thermal latency (the length of time a rat 158 
would leave its hindpaw on a hotplate; 2 s was baseline and 12 s was maximal nerve block). In 159 
general, block was considered successful if latency was > 7 s. Duration of nerve block was 160 
defined as the time for thermal latency to return to 7 s, the mid-point between baseline and 161 
maximal block.  162 
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Lipo-PPIX-TTX induced an initial nerve block lasting 8.3 ± 4.7 h (N = 4; Table S2, Figure 163 
4a). Insonation (3W/cm2, 1 MHz, 10 min) after the thermal latency returned below 4 s resulted in 164 
a return of nerve block for 0.7 ± 0.2 h. A second application of ultrasound, applied after the 165 
thermal latency returned to ≤ 4 s again, caused a return of nerve block with a duration of 0.2 ± 166 
0.2 h (Figure 4a). No nerve block was observed after a third ultrasound application. There was 167 
no animal mortality or increase in latency in the non-injected extremity (an established metric of 168 
systemic toxicity 27). However, 50% of animals injected with Lipo-TTX (3 of 6) died 3-10 h after 169 
injection, and 4 out of 6 rats showed an increase in latency in the non-injected extremity, 170 
possibly a reflection of the more rapid TTX release in this group (Fig. 3c). In the 3 animals that 171 
survived (Figure 4b), Lipo-TTX induced an initial nerve block of 17.2 ± 11.3 h, but insonation 172 
after the thermal latency returned below 4 s did not induce renewed nerve block (Figure 4b, P = 173 
0.001 between nerve block duration of Lipo-PPIX-TTX and Lipo-TTX after insonation) or dye 174 
release (Figure S4), demonstrating that PPIX was necessary for insonation-induced nerve block 175 
and cargo release. 176 
To assess the possibility that a formulation component other than TTX was causing nerve 177 
block, rats were injected at the sciatic nerve with PPIX-loaded liposomes without TTX (Lipo-178 
PPIX, Figure S5). Initial injection did not induce nerve block, nor did insonation 8 h after 179 
injection, demonstrating that TTX was necessary for nerve block. Animals directly treated with 180 
ultrasound in the absence of formulation administration did not develop nerve block upon 181 
insonation (Figure S6). 182 
To further demonstrate that the triggerablity of the Lipo-PPIX-TTX was due to ultrasound 183 
causing liposome lipid peroxidation, and not due to other effects of ultrasound, we injected rats 184 
at the sciatic nerve with TTX-containing liposomes (Lipo-DSPC-TTX) that did not contain PPIX 185 
or DLPC (which was replaced by DSPC, which cannot be peroxidated) and therefore could not 186 
be triggered in vitro (Figure S7a).  Lipo-DSPC-TTX caused an initial nerve block of 6.1 ± 3.6 h, 187 
which was comparable to the duration of initial block from Lipo-PPIX-TTX, but insonation did 188 
not induce nerve block (Figure S7). 189 
To further enhance the number and duration of ultrasound-triggerable nerve blocks, we co-190 
administered dexmedetomidine-loaded liposomes (Lipo-DMED, see Figure S8 for cryo-TEM 191 
image, see Methods for synthesis) with Lipo-PPIX-TTX at a 1:2 (Lipo-DMED: Lipo-PPIX-TTX) 192 
mass ratio. Dexmedetomidine, an α2-adrenergic agonists, prolongs the local anesthetic effects of 193 
TTX28.  Lipo-PPIX-TTX + Lipo-DMED caused an initial nerve block of 34.5 ± 5.0 h (Figure 5, 194 
Table S2). Repeated insonation (3 W/cm2, 1 MHz, 10 min) after the return to ≤ 4 s latency 195 
triggered three separate consecutive nerve blocks with durations of 1.8 ± 1.2 h, 0.9 ± 0.3 h, and 196 
0.5 ± 0.3 h respectively (Figure 5a, Table S2). The fourth ultrasound application induced an 197 
increase in hind-paw thermal latency to a mean of 5.3 ± 1.6 s. These results demonstrate that the 198 
co-administration of Lipo-DMED and Lipo-PPIX-TTX enhanced the repeatability and duration 199 
of nerve block compared to Lipo-PPIX-TTX alone. Administration of free TTX and DMED 200 
caused an initial nerve block of 9.27 ± 2.86 h. Insonation after thermal latency returned to 4 s did 201 
not cause an increase in thermal latency (Figure S9). This results demonstrate that that the 202 
residual free drug was not sufficient to induce nerve block upon insonation. A corollary to that is 203 
that ultrasound was not able to change the effect of the drugs so as to achieve nerve block. 204 
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The intensity and duration of the ultrasound-triggered nerve blocks could be controlled by 205 
varying the intensity and duration of the applied insonation after the initial nerve block from the 206 
administration of Lipo-DMED + Lipo-PPIX-TTX wore off (Figure 5b-d, Table S3). Insonation 207 
pulses of 2, 5, and 10 -min induced nerve blocks with a mean duration of 0.2 ± 0.2 h, 0.5 ± 0.2 h 208 
and 2.3 ± 0.9 h respectively (Figure 5b). Up to five separate consecutive ultrasound-triggerable 209 
nerve blocks were achieved by 5-min insonation (Table S3). The mean peak thermal latency was 210 
12 s for 10-min insonations, 9.9 ± 2.5 s for 5-min insonations, and 7.3 ± 1.4 s for 2-min 211 
insonations. The survival rate for all rats injected with Lipo-PPIX-TTX (with and without Lipo-212 
DMED; 20 animals in total) was 100%, and no increase in contralateral latency was observed, 213 
suggesting no clinically significant systemic distribution of TTX.  The duration of the 214 
ultrasound-triggered nerve block increased with increasing duration of insonation, with a plateau 215 
at 10 min (Figure 5c). 216 
To examine the effect of insonation intensity on ultrasound-triggered nerve block, 217 
insonations of different ultrasound intensities (10 min, 1-3W/cm2) were applied after the initial 218 
nerve block wore off (Figure 5d). The intensity and duration of nerve block increased with the 219 
intensity of insonation (Figure 5d, Table S4). No effective nerve block occurred below 220 
insonation intensities of approximately 1 W/cm2, above which duration of nerve block increased 221 
with ultrasound intensity.  222 
Tissue reaction 223 
In all animals that underwent neurobehavioral testing, the sciatic nerve and surrounding 224 
tissues were collected 4 days after the last ultrasound application. Animals administered PPIX-225 
loaded liposomes had reddish-brown (the color of PPIX) liposome deposits surrounding the 226 
sciatic nerve (Figure S10), demonstrating accurate liposome injection at the target site. Collected 227 
tissues were processed into hematoxylin & eosin-stained slides. All animals injected with 228 
liposomes showed mild inflammation at the injection site consistent with previous reports of 229 
perineural microparticle injection 29, but minimal inflammation was seen in the adjacent muscle. 230 
Foamy macrophages were observed at the injection site, showing particle uptake (Figure S11). 231 
All slides were scored for inflammation (0-4) and myotoxicity (0-6; see details in Methods). All 232 
groups had median inflammation scores of 1 (Figure S11, detailed scores in Table S5). The 233 
median myotoxicity score was 0 in all groups (Figure S11, Table S5). Insonation itself (in the 234 
absence of liposome administration) caused no significant inflammation (P=0.4 compared with 235 
normal tissue), myotoxicity (P=0.4 compared with normal tissue), or signs of other tissue injury 236 
(Figure S12) 1h after application. These data indicated that the ultrasound conditions used in this 237 
work do not induce tissue injury, immediately after the application, nor in the following four 238 
days.  239 
Sciatic nerves were stained with toluidine blue and sectioned. No significant neurotoxicity 240 
was observed in any animals (Figure S13). 241 
Ultrasound-guided injection and sonography of liposomes  242 
Ultrasound-guidance has become a standard of practice for peripheral nerve blockade30. It 243 
would be advantageous if ultrasound could be used both for procedural imaging and subsequent 244 
triggering. We assessed whether Lipo-PPIX could be visualized by ultrasound (Figure 6). PPIX-245 
loaded liposomes (Lipo-PPIX) were placed within ultrasonic gel in vitro and were imaged with 246 
high frequency ultrasound (40 MHz, ISPTA < 0.08 W/cm2). The liposome layer was densely 247 
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echogenic while the same volume of water was not (Figure 6a). Under the same experimental 248 
conditions, the echogenicity of Lipo was similar to that of (Figure S14) Lipo-PPIX. To show that 249 
Lipo-PPIX could be imaged at clinical imaging frequencies (2-20 MHz), Lipo-PPIX was 250 
successfully imaged with a 20 MHz transducer (Figure S16).   251 
In anesthetized animals, the sciatic nerve was identified under sonography at a tissue depth of 252 
approximately 7 mm (Figure S15, Figure 6b). A 23G needle was then advanced beside the sciatic 253 
nerve, and Lipo-PPIX was injected. A bright liposome deposit was observed on the sonogram 254 
after injection (Figure 6b), showing successful injection and imaging of liposomes at the target 255 
site. 256 
Discussion 257 
On-demand local anesthesia would allow patients to control the timing, duration and intensity of 258 
pain relief at will, ideally with a safe and non-invasive triggering system. Here we demonstrated 259 
that ultrasound allowed on-demand local anesthesia and that the intensity and duration of local 260 
anesthesia could be controlled by adjusting the intensity and duration of insonation (Figures 4-5). 261 
The system described here with TTX and DMED would provide about 36 hours of continuous 262 
initial nerve block, a duration very suitable for many perioperative contexts. It would then allow 263 
an additional half-day of on-demand nerve blockade, allowing personalized narcotic-free pain 264 
management. It is possible that such systems would mitigate the need for opioid prescription. 265 
Further developments of this proof-of-principle system could be designed to provide a shorter or 266 
longer initial nerve block, or a greater number of triggerable events, depending on the clinical 267 
context and anatomical site. 268 
As ultrasound is commonly used in the clinics, and hand-held therapeutic ultrasound devices 269 
are commercially available, controlling pain relief by adjusting the duration of ultrasound 270 
provides a simple method for on-demand local anesthesia. Ultrasound has been used safely for 271 
therapy at tissue depths of 2.3 to 5 cm31. The device used in this study was a commercial 272 
ultrasound employed in physiotherapy under conditions approved for clinical use. No tissue 273 
injury was seen.  274 
Ultrasound is a versatile energy source since it would allow image-guided injection, 275 
identification of the injectate in situ, confirmation of the appropriate site, and triggering of drug 276 
release. One could envision the use of a single ultrasound device by the clinician for pain 277 
treatments: using a diagnostic ultrasound setup (higher frequency, lower power) during injection, 278 
followed by formulation imaging, then using a therapeutic setup (lower frequency, higher power) 279 
to trigger further anesthetic events post-injection.  280 
The hypothesis that sonochemistry and the production of ROS played a major role in 281 
ultrasound-triggered cargo release is supported by the observation that liposomes loaded with 282 
PPIX produced a higher amount of ROS compared with blank liposomes (Figure 1), and that the 283 
incorporation of PPIX was necessary for triggered release of cargo (Figure 1, Figure 3, Figure 4). 284 
Production of ROS upon insonation in the presence of sonosensitizers could be due to several 285 
mechanisms. 32, 33 Ultrasound-induced cavitation can produce light (sonoluminescence)32, which 286 
could then activate the photosensitizer PPIX to produce ROS. Implosion of ultrasound-induced 287 
cavitation bubbles can also induce the formation of sonosensitizer-derived free radicals which 288 
generate ROS34. All these effects are dependent on inertial cavitation upon insonation33, which 289 
could be induced by the ultrasound conditions used here (3W/cm2, 1 MHz, continuous wave)35. 290 
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Another possible mechanism of the ultrasound-triggered cargo release may have been the 291 
mechanical effect of ultrasound. Liposome disruption by mechanical effects of ultrasound is 292 
known to be more efficient at frequencies much lower than those used in this study 36-38. In this 293 
study, we found that PPIX-loaded liposomes (Lipo-PPIX) were more mechanically stable (higher 294 
elastic modulus) than liposomes without PPIX (Lipo). This is in agreement with previous studies, 295 
where the incorporation of photosensitizers reduced the fluidity (raised the elastic modulus) of 296 
lipid membranes39 perhaps by enhancing hydrophobic interactions in the lipid bilayer, thereby 297 
stabilizing the liposomes25. The higher mechanical stability of PPIX-loaded liposomes would 298 
make them more difficult to be activated by ultrasound-induced mechanical effects. These data 299 
suggest that sonochemical effects, not mechanical effects, may have been the major mechanism 300 
of ultrasound-triggered release of TTX. 301 
The difference in elastic modulus between Lipo and Lipo-PPIX may also explain their 302 
release kinetics shown in Figure 3b and 3c. Decreasing in the fluidity of the lipid bilayer would 303 
decrease the rate of cargo release1. This is consistent with our observation in Figure 3, where 304 
Lipo was found to release its cargo more rapidly than Lipo-PPIX due to the higher fluidity of its 305 
lipid bilayers. 306 
The ultrasound triggerability of PPIX-loaded liposomes increased with PPIX loading at low 307 
PPIX concentrations, then decreased above a loading capacity of 0.3 % (Figure 1). This 308 
observation is consistent with previous reports25, where it was attributed to an increase in 309 
liposomal stability due to the hydrophobicity of the PPIX included in the lipid bilayer. It is also 310 
possible that above a certain concentration of PPIX, there is a self-quenching effect that 311 
diminishes the efficacy of PPIX in ROS generation (as has been described for aluminum and 312 
zinc phthalocyanines40, 41). The formulation that produced the highest amount of ROS was the 313 
same formulation that had the highest ultrasound-triggered dye release.  These results indicate 314 
that the decrease in ultrasound triggerability of formulations with PPIX loadings higher than the 315 
optimal PPIX loading may be due to the increase in PPIX-induced liposomal bilayer stability and 316 
the decrease in ROS generation of the formulation due to the self-quenching effect of 317 
sonosensitizers. 318 
TTX and other compounds42 that block the sodium channel at a site (site 1) different from 319 
that for conventional local anesthetics, have generally been used as scientific tools. However, 320 
their potent local anesthetic properties have long been recognized43, particularly if their systemic 321 
toxicity can be curtailed with other drugs27 or sustained release1. Recently, site 1 sodium channel 322 
blockers, including TTX and neosaxitoxin, have undergone clinical trials – the latter for 323 
peripheral nerve blockade44, 45. 324 
Particles containing local anesthetics – including those described here – generally serve as a 325 
depot, with drugs diffusing from the site of injection to adjacent nerves46. The present system 326 
could be applied in the same general set of applications as most local anesthetics: throughout the 327 
body, either injected throughout tissue planes (infiltration anesthesia) or along specific nerves or 328 
groups of nerves (regional anesthesia). In the latter applications, the particle depot is remote from 329 
the painful site; analgesia is provided by interruption of nerve signal proceeding to the brain. 330 
We hypothesized that ultrasound-induced TTX release was the main mechanism of 331 
ultrasound-triggered nerve block. Modulation of peripheral nerve activity by ultrasound 332 
(“neuromodulation”) 47 was another potential contributing factor. In our experiments, insonation 333 
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of animals injected with PPIX-loaded liposomes without TTX did not induce an increase in 334 
thermal latency (Figure S5), nor did insonation of uninjected animals (Figure S6). These 335 
experiments suggest that ultrasound itself did not cause nerve block in the absence of TTX. 336 
Ultrasound did not cause nerve block after recovery of analgesia from TTX + DMED solution 337 
(Figure S9) although it did after recovery from Lipo-PPIX-TTX + Lipo-DMED – indicating that 338 
the return of nerve block after insonation of Lipo-PPIX-TTX + Lipo-DMED was due to the 339 
release of TTX from the liposomes. Moreover, if the return of nerve block were due to a direct 340 
effect of ultrasound on free TTX or on nerve, one would have expected the return to occur in 341 
both cases since the local concentrations of TTX would be equal, nerve block having just worn 342 
off. We cannot exclude the possibility that ultrasound could affect nerve block, only that it did 343 
not do so here. 344 
The eventual lack of effect after multiple triggering of PPIX-loaded liposomes in vitro could 345 
be attributable to a number of factors. The ultrasound-triggered peroxidation is irreversible, 346 
limiting the number of triggerable (peroxidation-dependent) events. Another potential 347 
contributing factor is the depletion of drug remaining in the liposomal reservoir due to basal 348 
release and repeated triggers. In vivo, it is possible that degradation and/or removal of particles 349 
could also play a role. 350 
We sought to improve the performance of the system by increasing the effect of each packet 351 
of TTX released. We did so by co-delivering dexmedetomidine (DMED), an α2-adrenergic 352 
agonist that prolongs the therapeutic effects of local anesthetics28, 48, 49.  Since the DMED was 353 
contained in separate liposomes than the TTX, the effect of DMED was likely a pharmacological 354 
one rather than due to increased TTX release. DMED increased the duration of the initial nerve 355 
block, as well as the duration and number of triggered nerve blocks. (Figure 4-5, Table S2). One 356 
potential mechanism of such synergy by DMED’s inhibition of hyperpolarization-activated 357 
cation current48. Another contributing factor is local α2-adrenergic receptor mediated 358 
vasoconstriction 49, 50, which inhibits redistribution of the local anesthetic, maintaining a high 359 
local concentration at the target tissue. 360 
Many local anesthetic drug delivery systems continue to release drug after the local effect has 361 
ended58, 59. The resulting period of subclinical anesthetic release can be very useful: co-delivery 362 
of drugs that potentiate the effect of the anesthetic can render the subclinical concentration 363 
effective1, 60, 61. This was seen here in the marked prolongation of initial block due to the addition 364 
of DMED to the formulation. All released drug will eventually enter the systemic circulation and 365 
be eliminated, renally in the case of TTX 62. Of note, the second drug can also be beneficial in 366 
mitigating local toxicity of TTX, particularly if it is a local vasoconstrictor, as are α2-adrenergics 367 
agonists 63 such as DMED.  368 
The mild inflammation from liposomes injections is generally considered safe51 52, and we 369 
saw no significant tissue toxicity from the liposomes or insonation (the ultrasound parameters 370 
used in this study are used for therapeutic ultrasound53). TTX has also been shown to have 371 
minimal myo- and neuro-toxicity21, 22. PPIX is the active agent of FDA approved drug ALA54.  372 
The main ROS that are involved in sonosensitization are hydroxyl radicals and singlet oxygen.  373 
The former has a half-life of 10-9 s and diffusion distance of 0.06 nm55, 56, the latter has a half-life 374 
of 10-6 s and diffusion distance of 268 nm57. These distances are small compared to the length 375 
scales of tissue, suggesting a low likelihood of toxicity, consistent with the results of this study. 376 
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Sustained release local anesthetic systems act by continuously releasing doses high enough to 377 
be effective over an extended period. Consequently those that can achieve very long durations of 378 
effect commonly contain substantial quantities of drug 1, 60.  The sustained release also prevents 379 
systemic toxicity; the fact that the drug payload is contained in a vast number of separate 380 
particulate compartments is one safeguard against catastrophic dumping of drug with resulting 381 
toxicity. Another important safety consideration in translating such systems into humans lies in 382 
the difference in size between humans and rats. The dose required for a given local anesthetic 383 
endpoint tracks weakly with animal size 64. In contrast, local anesthetic toxicity tracks fairly 384 
linearly with animal size, in proportion to the increased volume of distribution. Therefore the 385 
therapeutic index would be expected to increase in larger animals. This was seen in humans who 386 
were able to achieve safe prolonged local anesthesia with neosaxitoxin, a compound that acts by 387 
a mechanism similar to that of tetrodotoxin 45, 65, 66. The doses used in those humans would have 388 
been uniformly fatal in rats. 389 
Finally, liposomes may have intrinsic echogenic properties that are dependent on their lipid 390 
composition, concentration and vesicle structure. Oligo- and multilamellar liposomes, like the 391 
ones used in this study, are more echogenic than unilamellar liposomes 67, providing the ability 392 
to image them via ultrasound. Here, 40 MHz was used to provide higher resolution imaging to 393 
better target the rat sciatic nerve, which is much smaller than that of humans. This imaging 394 
frequency is often used in small animal imaging 68. In the clinic, ultrasound frequencies of 2 - 20 395 
MHz are used for sonography. Our liposomes can be imaged at those frequencies (Figure S16).  396 
We have developed an ultrasound-triggerable, on-demand nerve block system that allows 397 
effective control of nerve block duration and intensity simply through the duration and intensity 398 
of insonation. Diagnostic ultrasound allowed guided injection and imaging of the formulation, 399 
whereas therapeutic ultrasound induced adjustable and repeatable nerve block. 400 
 401 
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Methods 418 
Liposome preparation. Liposomes were prepared by the thin-film hydration method, as 419 
reported3. In brief, the lipid formulation [DSPC (Avanti Polar Lipids, Alabaster, AL, USA), 420 
DLPC (Avanti Polar Lipids, Alabaster, AL, USA), DSPG (Genzyme, Cambridge, MA, USA), 421 
and cholesterol (Sigma, St. Louis, MO, USA) at molar ratio 3:3:2:3], along with the indicated 422 
amount of the sonosensitizer PPIX, was dissolved in a solution of chloroform:methanol 9:1. The 423 
solvent was evaporated under reduced pressure, and the lipid was redissolved in t-butanol, 424 
followed by freeze-drying. The lipid cake was hydrated with PBS, TTX solution (0.375 mg/mL 425 
PBS; Abcam, Cambridge, MA, USA), or sulforhodamine B solution (10 mg/mL PBS; Aldrich, 426 
St. Louis, MO, USA). After 10 freeze–thaw cycles, the solution was dialyzed against PBS for 48 427 
h in a dialysis tube with a molecular mass cut-off of 1000 kDa. The dialysis media were changed 428 
with fresh PBS at least twice a day. Lipo-DMED was made following the same procedure, but 429 
with PPIX not included in the formulation and with hydration in 1 mg/mL of DMED in PBS 430 
solution. 431 
Liposome characterization. Liposome size was determined with a Beckman Coulter Multisizer 432 
3 (Beckman Coulter, Indianapolis, IN, USA). Liposomal sulforhodamine B content was 433 
determined by UV-Vis absorption (λmax = 565 nm) after disrupting the liposomes with octyl β-434 
D-glucopyranoside (OGP) (Sigma-Aldrich, Milwaukee, WI, USA)3. Liposomal PPIX content 435 
was determined by UV-Vis absorption at 402 nm after disrupting the liposomes in ethanol69. 436 
Liposomal TTX content was determined by ELISA (Reagen, Moorestown, NJ, USA) after 437 
removing the lipid fraction using the Bligh and Dyer method70. 438 
Reactive oxygen species (ROS) detection. Carboxy-H2DCFDA (Molecular Probes, OR, USA), 439 
is a non-fluorescent reagent commercially available for the detection of ROS71, 72. Upon 440 
exposure to ROS, it undergoes oxidation and forms the the highly fluorescent 2',7'-441 
dichlorofluorescein (DCF), which can be detected upon fluorescence measurements (Scheme S2). 442 
Carboxy-H2DCFDA was dissolved in ethanol and diluted 100 fold in PBS, followed by the 443 
addition to liposome suspension to a final concentration of 10 μM. The fluorescence emission at 444 
527 nm (excitation: 493 nm) was monitored after applying ultrasound to 1 mL of the solution at 445 
3 W/cm2 for 10 min.  446 
Lipid peroxidation. To determine the degree of lipid peroxidation in the system, we followed a 447 
reported Fe-based colorimetric method73. Briefly, 0.9 mL of a methanolic solution of xylenol 448 
orange (100 μM), Fe2+ (250 μM), H2S04 (25 mM) and butylated hydroxytoluene (4 mM) were 449 
incubated with 100 μL of sample for 30 min at room temperature. The absorbance at 560 nm was 450 
measured.  451 
 In vitro release of fluorescent dye. Self-quenching sulforhodamine B was used as a hydrophilic 452 
model dye3. To measure ultrasound or 400 nm light-triggered release, sulforhodamine B 453 
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liposomes were diluted 200-fold in PBS. For ultrasound triggered experiments, 1 mL of the 454 
suspension was placed in a 20-mL glass vial and sealed with a latex membrane. Ultrasonic gel 455 
was then placed between the latex membrane and the ultrasonic source. Ultrasound was applied 456 
at the reported power and duration. For light-triggered experiments, the diluted liposome solution 457 
was directed exposed under a 400-nm light source for 10 min, 5 mW/cm2. The fluorescent 458 
intensity (excitation/emission: 560/580 nm) was recorded. The release of dye from liposomes 459 
upon ultrasound or light exposure was quantified according to the following equation3:  460 
Cumulative	Releaseሺ%ሻ = 	 ܨ − ܨ଴ܨ௕௥௘௔௞ − ܨ଴ 	× 100 
F = Fluorescence of solution upon ultrasound exposure F0 = Fluorescence of liposome 461 
solution prior to ultrasound exposure Fbreak = Fluorescence of surfactant (octyl β-D-462 
glucopyranoside)-disrupted liposome solution.  463 
Atomic force microscopy. Silicon wafer (Ted Pella, Inc., Redding, CA, USA) was 464 
functionalized by 3-Triethoxysilylpropylamine (APTES, Sigma-Aldrich, Milwaukee, WI, USA) 465 
using a previously reported method74.  Liposomes were placed onto the wafer and left settled for 466 
1 h under room temperature. The DNP-10 AFM tip (Bruker Nano Inc., Camarillo, CA, USA) 467 
was used. The AFM machine model was MFP-3D Bio (Asylum Research, Goleta, CA, USA). 468 
Force curves were measured and analyzed by the computational program Igor Pro (Wavemetrics, 469 
Lake Oswego, OR, USA). The Hertzian model was applied to obtain the elastic moduli as 470 
previously reported 75. 471 
In vivo imaging with dye-loaded liposomes (Lipo-PPIX-SRho). Lipo-PPIX-SRho (150μL) 472 
was injected subcutaneously and  the fluorescence intensity of the released fluorophore was 473 
detected and quantified using an in vivo imaging system4 (IVIS spectrum, Caliper Life Sciences, 474 
Waltham, MA, USA) before and after ultrasound application (3W/cm2, 10 min, 1 MHz), at 475 
excitation and emission wavelengths of 535 nm and 580 nm. 476 
In vitro TTX release. TTX release experiments were performed by placing 150 μL of TTX-477 
loaded liposomes into a Slide-A-Lyzer MINI dialysis device (Thermo Scientific, Tewksbury, 478 
MA, USA) with a 20,000 MW cut-off. The sample was dialyzed against 14 mL PBS and 479 
incubated at 37oC on a platform shaker at 150 rpm (New Brunswick Innova 40, Eppendorf, 480 
Hauppauge, NY, USA)3. At predetermined intervals, the dialysis solution was exchanged with 481 
fresh PBS. To measure the ultrasound-triggerability of the liposomes, ultrasound was applied (3 482 
W/cm2, 1 MHz) for 10 min at the 5-h time point. TTX concentration was determined by ELISA 483 
(Reagen LLC, Moorestown, NJ, USA). 484 
Animal Studies. Animal studies were performed according to protocols approved by the Boston 485 
Children’s Hospital Animal Care and Use Committee following the guidelines of the 486 
International Association for the Study of Pain76. Adult male Sprague–Dawley rats (Charles 487 
River Laboratories, Wilmington, MA, USA) weighing 300–400 g were housed in groups under a 488 
12-h/12-h light/dark cycle with lights on at 7:00 AM. Animals were randomly assigned to each 489 
group. Under brief isoflurane-oxygen anesthesia, the animals were injected with 200 μL of 490 
liposomes with or without 100 μL of Lipo-DMED, using a 23G needle. The injection was 491 
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performed at the sciatic nerve as described3 with the needle introduced posteromedial to the 492 
greater trochanter, then the animals underwent neurobehavioral testing (see following paragraph) 493 
at predetermined intervals. Once the initial nerve block wore off, animals were exposed to 494 
ultrasound (New Pocket Sonovit, New Age Italia Srl, Lugo, RA, Italy) under brief anesthesia, at 495 
the time points and durations described in Results. The process was repeated until there was no 496 
further nerve block. Pharmacokinetic studies were performed by injection SRho-loaded 497 
liposomes at a dosage of 1.5 mg/kg and constant volume of 200 µL. The blood was processed 498 
using a previously reported method77. In brief, at predetermined time points, blood was collected 499 
from the tail. After centrifugation, the supernatant was collected. Methanol was then added at a 500 
1:1 vol ratio. Samples were settled overnight at 4oC. The supernatant was collected. The 501 
concentration of SRho was analyzed by fluorescence (excitation/emission: 560 /580 nm). 502 
Sensory nerve block was examined at different time points by a modified hotplate test (hind-503 
paw thermal latency) as reported 3, 78. The researcher who performed the neurobehavioral test 504 
was blinded to the sample group allocation. The rat’s hindpaw was placed on a preheated hot 505 
plate at 56 °C. The time until the animal withdrew its paw foot (the thermal latency) was 506 
recorded. Animals that did not retract the paw after 12 s were removed manually to prevent 507 
thermal injury. 2 s was considered baseline.  Durations of sensory block were calculated as the 508 
time required for thermal latency to return to 7 s (the middle point between baseline and 509 
maximum possible thermal latency). Measurements were repeated three times at each time point, 510 
and the median was used for further data analysis.  511 
Histology. Rats were euthanized by carbon dioxide 4 d after the last ultrasound exposure. The 512 
sciatic nerve and surrounding tissue were harvested and underwent standard procedures to 513 
produce H&E-stained slides, following the same protocol as previously reported3. Inflammation 514 
and myotoxicity of the samples were scored as reported79. All scoring and other histological 515 
assessments were performed by an observer (A.Y.R.) blinded as to the nature of the individual 516 
samples. The inflammation score was a subjective quantification of severity in which 0 was 517 
normal and 4 was severe inflammation. The myotoxicity score was determined based on nuclear 518 
internalization and regeneration of myocytes, which are representative characteristics of local 519 
anesthetics’ myotoxicity. Nuclear internalization was characterized by myocytes having nuclei 520 
located away from their usual location at the periphery of the cell. Regeneration was 521 
characterized by the presence of shrunken myocytes with basophilic cytoplasm. The scoring 522 
scale was as follows: 0 = normal; 1 = perifascicular internalization; 2 = deep internalization 523 
(more than five cell layers); 3 = perifascicular regeneration; 4 = deep tissue regeneration (more 524 
than five cell layers); 5 = hemifascicular regeneration; 6 = holofascicular regeneration. 525 
Nerve tissue was processed with toluidine blue staining as previously reported 3. In brief, the 526 
sciatic nerve tissues were fixed in Karnovsky’s KII Solution (2.5 % glutaraldehyde, 2.0 % 527 
paraformaldehyde, 0.025 % calcium chloride in 0.1 M cacodylate buffer, pH 7.4), followed by 528 
postfixation with osmium tetroxide. Samples were then stained with uranyl acetate, dehydrated 529 
in graded ethanol solutions, and infiltrated with propylene oxide/TAAB 812 Resin (TAAB 530 
Laboratories, Aldermaston, Berks, United Kingdom) mixtures. Tissue sections were stained with 531 
toluidine blue. 532 
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Ultrasound imaging. The Visualsonics Vevo 2100 (VisualSonics Inc., Toronto, ON, Canada) 533 
with an MS-550D 40 MHz or an MS-250 20 MHz transducer at B-mode was used for 534 
sonography. In vitro imaging was achieved by applying 100 µL of liposome or water on top of a 535 
layer of ultrasonic gel, and covering it with another layer of gel. The top layer gel was in contact 536 
with the transducer.  537 
Sprague–Dawley rats of 300 – 400 g were anesthetized with isoflurane-oxygen and 538 
positioned under the ultrasound transducer. Ultrasonic gel was applied between the transducer 539 
and the rat. A 23G needle was used to inject 200 µL of Lipo-PPIX. The needle was placed beside 540 
the sciatic nerve as shown from the real-time sonogram prior to liposome administration (Fig. 541 
S6).  542 
Statistical Analysis. Statistical comparisons were performed using the Student t-test (one-sided) 543 
unless stated otherwise. The variance between the groups that were statistically compared was 544 
similar. Thermal latencies, inflammation and myotoxicity scores were reported by medians and 545 
quartiles due to its ordinal or non-Gaussian character. All other data were described by means 546 
and standard deviations. 547 
Data Availability. The authors declare that all data supporting the findings of this study are 548 
available within the paper and its supplementary information 549 
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 729 
Figure 1. Ultrasound triggerability with PPIX-loaded liposomes. (a) Effect of PPIX loading on 730 
ROS generation (measured by fluorescent assay) by liposomes after 10-min insonation at 1 MHz, 731 
3 W/cm2. (b) Time course of lipid peroxidation in liposomes of optimal PPIX loading (0.3 % 732 
[mg PPIX/mg (PPIX+lipid) X 100 %]) under continuous ultrasound (US) exposure (3 W/cm2, 1 733 
MHz). See Methods for details.  (c) Effect of PPIX loading in liposomes (mg PPIX / mg 734 
lipid+PPIX X 100 %) and of presence of DLPC on sulforhodamine B release after insonation 735 
(3W/cm2, continuous application, 1 MHz, 10 min). (d-f) In vitro dye release as a function of (d) 736 
ultrasound duration and frequency (3W/cm2, continuous application), (e) ultrasound intensity (10 737 
min, 1 MHz, continuous application), and (f) duty cycle (1 MHz, 10 min, 3 W/cm2). Data are 738 
means ± SD, N=4. *P<0.05. All individual data points are listed in Table S6-S11.  739 
  740 
P.19 
 
 741 
Figure 2. Ultrasound (US)-triggered dye release from Lipo-PPIX-SRho. (a) Repeated ultrasound-742 
triggered dye release (cumulative % of total); insonation (5 min, 1 MHz, 3W/cm2, continuous) is 743 
indicated by arrows. Data are means ± SD. N=5 for no US group, N=6 for US group. Individual 744 
data points are listed in Table S12-S13. (b) Ultrasound triggering of dye release from 745 
subcutaneously injected Lipo-PPIX-SRho (1 MHz, 10 min, continuous application, 3 W/cm2), 746 
N=4; P < 0.001 for comparison of the average integrated epifluorescence of non-ultrasound 747 
triggered and ultrasound-triggered animals. Individual data points are listed in Table S14. 748 
P.20 
 
 749 
Figure 3. TTX-loaded liposomes. (a) Representative cryo-transmission electron microscopy 750 
micrograph of Lipo-PPIX-TTX. Scale bar = 200 nm. (b-c) In vitro TTX release (cumulative % of 751 
total) at 37oC from (b) Lipo-PPIX-TTX and (c) Lipo-TTX with and without ultrasound (US). 752 
Arrows represent the application of ultrasound (1 MHz, 3 W/cm2, continuous, 10 min) at the 5 h 753 
time point. Data are means ± SD, N = 4. All individual data points are listed in Table S15-S16.  754 
At 9 h of incubation, P=0.005 in panel b and P=0.39 in panel c for the comparison between 755 
samples with and without insonation.  756 
  757 
P.21 
 
 758 
 759 
Figure 4. Representative (from one animal of 4) timecourses of thermal latency after injection of 760 
liposomal formulations and subsequent insonation. Animals were injected with 200 µL of (a) 761 
Lipo-PPIX-TTX, or (b) Lipo-TTX. Insonation (3 W/cm2, 1 MHz, 10 min) is indicated by black 762 
arrows. The triggered nerve blocks are magnified to the right. Individual data points for all 763 
animals are listed in Table S17-S18. 764 
 765 
 766 
  767 
P.22 
 
 768 
Figure 5. Effect of ultrasound on thermal latency after injection of Lipo-PPIX-TTX + Lipo-769 
DMED and subsequent insonation. (a) Representative (from 1 of 4 rats) timecourse with 10-min 770 
insonations (black arrows, 1 MHz, continuous application, 3 W/cm2). The triggered nerve blocks 771 
are magnified to the right. Individual data points for all 4 animals are listed in Table S18. (b)  772 
Effect of insonation duration (2, 5, or 10 min) on the timecourse of the first ultrasound-triggered 773 
nerve block (after the initial nerve block wore off). Data are medians ± quartiles, N=4. (c) Effect 774 
of duration of insonation on the duration of the first triggered nerve block. Data are means ± SD, 775 
N=4. (d)  Effect of insonation intensity (10 min and 1, 2, or 3 W/cm2) on the timecourse of the 776 
first ultrasound-triggered nerve block (after the initial nerve block wore off). Data are medians ± 777 
quartiles, N=4. Individual data points from all animals are listed in Table S19-S22. 778 
 779 
 780 
  781 
P.23 
 
 782 
Figure 6. Ultrasonography of Lipo-PPIX. (a) In vitro comparison of echogenic contrast of Lipo-783 
PPIX-TTX and water. (b) Sonograms before and after ultrasound guided perisciatic injections of 784 
Lipo-PPIX. Sonograms were taken with a 40-MHz ultrasound transducer. Scale bars are 1 mm.  785 
 786 
 787 
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